Shamzah Araf
Shamzah Araf
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
2Centre for Genomic Health, Queen Mary University of London, London, UK
1,2,✉,#,
Jun Wang
Jun Wang
3Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
3,#,
Koorosh Korfi
Koorosh Korfi
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Celine Pangault
Celine Pangault
4UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France
4,
Eleni Kotsiou
Eleni Kotsiou
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Ana Rio-Machin
Ana Rio-Machin
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Tahrima Rahim
Tahrima Rahim
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
James Heward
James Heward
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Andrew Clear
Andrew Clear
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Sameena Iqbal
Sameena Iqbal
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Jeff K Davies
Jeff K Davies
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Peter Johnson
Peter Johnson
5Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK
5,
Maria Calaminici
Maria Calaminici
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Silvia Montoto
Silvia Montoto
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Rebecca Auer
Rebecca Auer
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Claude Chelala
Claude Chelala
3Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
3,
John G Gribben
John G Gribben
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Trevor A Graham
Trevor A Graham
6Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK
6,
Thierry Fest
Thierry Fest
4UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France
4,
Jude Fitzgibbon
Jude Fitzgibbon
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,
Jessica Okosun
Jessica Okosun
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
1,✉
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
2Centre for Genomic Health, Queen Mary University of London, London, UK
3Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
4UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France
5Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK
6Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK
Subject terms: Cancer genetics, Cancer genomics, B-cell lymphoma
© The Author(s) 2019
This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.